Scarica l'app Stockscreener
1.51
4.43%
-0.07
Dopo l'orario di chiusura:
1.51
Precedente Chiudi:
$1.58
Aprire:
$1.5
Volume 24 ore:
1.26M
Relative Volume:
0.40
Capitalizzazione di mercato:
$83.58M
Reddito:
-
Utile/perdita netta:
$-82.44M
Rapporto P/E:
-0.8032
EPS:
-1.88
Flusso di cassa netto:
$-66.75M
1 W Prestazione:
-9.58%
1M Prestazione:
-20.94%
6M Prestazione:
-58.74%
1 anno Prestazione:
-69.80%
Intervallo 1D:
$1.43
$1.53
Intervallo di 1 settimana:
$1.43
$1.65
Portata 52W:
$1.43
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Nome
Black Diamond Therapeutics Inc
Settore
Industria
Telefono
617-417-5868
Indirizzo
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Confronta BDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.51 | 83.58M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-31 | Iniziato | Raymond James | Outperform |
| 2023-07-14 | Iniziato | Piper Sandler | Overweight |
| 2023-06-30 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-03-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-03-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-01-07 | Iniziato | Wedbush | Outperform |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | Canaccord Genuity | Buy |
| 2020-02-24 | Iniziato | Cowen | Outperform |
| 2020-02-24 | Iniziato | JP Morgan | Overweight |
| 2020-02-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Small Cap Stocks To Follow TodayMarch 19th - MarketBeat
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com India
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Black Diamond Therapeutics Reports 2024 Financial Results - MSN
Black Diamond Therapeutics: In Decline, But Why? (NASDAQ:BDTX) - Seeking Alpha
Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $1.76 amid market challenges - Investing.com Australia
BDTX stock touches 52-week low at $1.76 amid market challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Brokers Issue Forecasts for BDTX Q1 Earnings - Defense World
Stifel Nicolaus Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00 - Defense World
Wedbush Reiterates Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc Azioni (BDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):